The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Cann Global (CGB) shares jump after its cannabis hard pills were received in Australia
  • Cann began importing the cannabis pills in late March following the green light by Health Canada
  • Currently, two of its six products have been shipped, with the remaining four arriving soon
  • The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs
  • On market close, Cann is up 20 per cent and trading at 0.6 cents per share

Cann Global (CGB) shares jumped today after its cannabis hard pills were received in Australia.

The company launched its products last October with its Canadian joint venture partner Canntab Therapeutics.

Cann began importing the cannabis pills in late March after receiving the green light by Health Canada.

Currently, two of its six products have been shipped, with the remaining four arriving soon.

According to Cann, its products are unique because of the patented hard pill form in which they come in, allowing for more precise dosing.

The cannabidiol formulations will be available for ordering by pharmacies once the shipment has been cleared in customs.

“The products can be prescribed by practitioners via the Special Access Scheme Category B application pathway,” the company told the market.

Cann Global will update the market when the remaining four products have arrived in Australia.

On market close, Cann is up 20 per cent and trading at 0.6 cents per share.


cgb by the numbers
More From The Market Online
The Market Online Video

Syntara shows encouraging first signals it can impact the path to Parkinson’s

Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence
Diabetes concept

Entropy reports 50% remission in Phase 2 psychedelic trial for binge eating disorder

Entropy Neurodynamics says its Phase 2 trial of TRP-8803 delivered 50% remission in all treatment-resistant binge…

Syntara reports encouraging early Parkinson’s trial results

Syntara has reported statistically significant reductions in brain inflammation in an early-stage Parkinson's disease study.

OncoSil Medical files for US FDA approval for specialist device

OncoSil Medical has hit a key milestone in its plans to commercialise its unique OncoSil device…